NASDAQ:PCRX Pacira BioSciences Q3 2025 Earnings Report $22.35 -0.71 (-3.08%) Closing price 04:00 PM EasternExtended Trading$22.14 -0.21 (-0.96%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Pacira BioSciences EPS ResultsActual EPSN/AConsensus EPS $0.66Beat/MissN/AOne Year Ago EPSN/APacira BioSciences Revenue ResultsActual RevenueN/AExpected Revenue$182.86 millionBeat/MissN/AYoY Revenue GrowthN/APacira BioSciences Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Pacira BioSciences Earnings HeadlinesPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives $33.40 Average Price Target from BrokeragesSeptember 29, 2025 | americanbankingnews.com1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.October 10 at 2:00 AM | Base Camp Trading (Ad)Pacira BioSciences (PCRX): Evaluating Valuation After Recent Share Price MomentumSeptember 17, 2025 | finance.yahoo.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comSee More Pacira BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email. Email Address About Pacira BioSciencesPacira BioSciences (NASDAQ:PCRX) is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain. In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. The company has advanced clinical research in areas such as extended-release meloxicam formulations for soft tissue and orthopedic procedures, aiming to further expand its portfolio of non-opioid pain therapies. Pacira collaborates with healthcare providers and research partners to support clinical trials and to explore potential new indications for its proprietary technologies. Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira BioSciences markets its products throughout the United States and in select international territories. The company emphasizes education and training for healthcare professionals to ensure the safe and effective use of its therapies. Pacira’s operations encompass regulatory affairs, medical affairs, and commercial functions, all dedicated to advancing patient-centered approaches to pain management.View Pacira BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
